Loading cancer entity…
Loading cancer entity…
Clinical trials
28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | completed | Phase 2 | 36 | Aprea TherapeuticsINDUSTRY | 3 | Mar 17, 2025 | clinicaltrials |
| NCT06787170 |
| Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer(PPRPHGSOC) |
| completed |
| — |
| 1,129 |
| The First People's Hospital of YunnanOTHER |
| 1 |
| Jan 23, 2025 |
| clinicaltrials |
| NCT05188781 | Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer | completed | — | 34 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01853306 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 71 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials